These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37388902)

  • 1. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer.
    Li LC; Chen XW; Fang L; Jian CL; Yu YX; Liao XY; Sun JG
    Can Respir J; 2023; 2023():4689004. PubMed ID: 37388902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
    Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
    Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
    Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
    Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
    BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kuribayashi T; Ohashi K; Nishii K; Ninomiya K; Tsubata Y; Ishikawa N; Kodani M; Kanaji N; Yamasaki M; Fujitaka K; Kuyama S; Takigawa N; Fujimoto N; Kubota T; Inoue M; Fujiwara K; Harita S; Takata I; Takada K; Okawa S; Kiura K; Hotta K
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):89. PubMed ID: 38347279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
    Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
    Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
    Ichihara E; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Ochi N; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Cancer Immunol Immunother; 2021 Jan; 70(1):101-106. PubMed ID: 32648165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
    Le X; Negrao MV; Reuben A; Federico L; Diao L; McGrail D; Nilsson M; Robichaux J; Munoz IG; Patel S; Elamin Y; Fan YH; Lee WC; Parra E; Solis Soto LM; Chen R; Li J; Karpinets T; Khairullah R; Kadara H; Behrens C; Sepesi B; Wang R; Zhu M; Wang L; Vaporciyan A; Roth J; Swisher S; Haymaker C; Zhang J; Wang J; Wong KK; Byers LA; Bernatchez C; Zhang J; Wistuba II; Gibbons DL; Akbay EA; Heymach JV
    J Thorac Oncol; 2021 Apr; 16(4):583-600. PubMed ID: 33388477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
    Wang L; Ren Z; Yu B; Tang J
    J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
    Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.
    Lawal B; Wu ATH; Huang HS
    Front Immunol; 2022; 13():872470. PubMed ID: 35655775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
    Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
    Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
    Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
    BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research Progress in Immune Checkpoint Inhibitors Combination Therapy Applied to 
Non-small Cell Lung Cancer after EGFR Mutation-targeted Therapy Resistance].
    Li J; Yao X; Qiu L; Zhang R; Wang G
    Zhongguo Fei Ai Za Zhi; 2023 May; 26(5):392-399. PubMed ID: 37316449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of Immune Checkpoint Inhibitors in EGFR Mutant 
Advanced Non-small Cell Lung Cancer].
    Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
    Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
    Zhao F; Wang M; Zhu J
    Cancer Med; 2021 Sep; 10(17):6099-6113. PubMed ID: 34250747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.